Heron Therapeutics (HRTX) Share-based Compensation (2010 - 2026)

Heron Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 18.52% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (down 10.7% YoY), and the FY2025 full-year result was $10.3 million, down 20.24% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.0 million, up from $2.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $13.9 million in Q2 2023, with the low at $2.2 million in Q4 2025.
• Historically, Share-based Compensation has averaged $6.0 million across 5 years, with a median of $4.3 million in 2023.
• Annual changes were most pronounced in 2023 — Share-based Compensation soared 34.26% — and 2024, when it slumped 67.12%.
• Heron Therapeutics' Share-based Compensation stood at $10.5 million in 2022, then plunged by 58.87% to $4.3 million in 2023, then sank by 46.92% to $2.3 million in 2024, then decreased by 5.05% to $2.2 million in 2025, then jumped by 36.58% to $3.0 million in 2026.
• The last three Share-based Compensation figures came in at $3.0 million (Q1 2026), $2.2 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.